Mealey's (March 22, 2018, 1:28 PM EDT) -- NEW YORK — An Israeli clinical stage biopharmaceutical company that develops combination drugs for the treatment of osteoarthritis and hypertension issued material misrepresentations and omissions concealing that the company’s CEO falsified...
Company Shown To Have Concealed Falsified Study Results In Stock Drop Suit
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login